Mesothelioma
Canadian researchers have discovered a cause of chemotherapy resistance in mesothelioma and other cancers. This is great news because this can lead to new treatments being created to combat the incurable cancer. There are other types of treatments approved for mesothelioma, but they might not work and chemotherapy could be the best option. The Canadian…
Primary Outcome Measures Occurrence of Dose Limiting Toxicity [ Time Frame: over the first 21 days of dosing ] Incidence of Adverse and Serious Adverse Events Occurrence of General Toxicity [ Time Frame: through study completion, an average of 30 months ] Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations Secondary Outcome Measures Tumor Response…
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of the treatment, believes that it…
A study looking at a system that connects doctors and patients with a smartphone is showing that it could make the management of mesothelioma symptoms easier. Mesothelioma is a fast growing and aggressive cancer that has many different physical symptoms. Researchers in the United Kingdom are looking at a mesothelioma specific symptom management system. The…
An altered herpes virus is being tested in mesothelioma patients, and the results show that it can stabilize the growth of mesothelioma tumors. Half of the patients given the virus responded to the treatment, which is very promising. Thirteen patients were injected with a version of HSV (herpes causing virus) that seeks out cancer cells.…
Vitamin D3 could potentially be used to slow down mesothelioma. There are promising results coming from a study in Italy studying the possibilities of Vitamin D3 on mesothelioma cells. Results from the study are showing that it could prevent mesothelioma cells from growing and spreading. Calcitriol, the biologically active form of Vitamin D3, has shown…
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment or even a cure, so…
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient’s tumor shrink or stop growing.
The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a first line setting. Doctors doing…
